Core Viewpoint - Immvira Bioscience Inc. (亦诺微医药) has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC acting as joint sponsors. This marks the company's second attempt to go public, having previously submitted an application in June 2025 [1]. Company Overview - Immvira Bioscience Inc. is a biotechnology company focused on clinical demand-driven solutions, specializing in the discovery, development, production, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has established a product pipeline that includes two oncolytic immunotherapy products targeting solid tumors and five engineered exosome products with clinical application potential or direct commercialization prospects [4]. - The core product, MVR-T3011, is a novel oncolytic immunotherapy in Phase II trials, utilizing a modified herpes simplex virus type 1 (HSV-1) combined with anti-PD-1 antibodies and IL-12 expression. It is being evaluated as a monotherapy and in combination therapies for various cancers, including bladder cancer and head and neck squamous cell carcinoma [4]. Financial Information - The company reported revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the fiscal years ending December 31, 2023, and 2024, and for the nine months ending September 30, 2025, respectively [6][7]. - Losses for the same periods were approximately RMB 481.753 million, RMB 523.755 million, and RMB 337.910 million, primarily due to research and administrative expenses [8]. Industry Overview - The global oncolytic immunotherapy market is currently in its early stages, characterized by a limited number of commercialized products and low clinical adoption rates. The market is expected to experience significant growth, with projections indicating an increase from USD 87.1 million in 2024 to USD 1.56 billion by 2028, representing a compound annual growth rate (CAGR) of 105.7% [10]. - In China, the oncolytic immunotherapy market is anticipated to grow from USD 6.3 million in 2024 to USD 223 million by 2028, with a CAGR of 143.9% during the same period [15].